Novel Drug Design Solutions for Poorly Addressed Medical Conditions

DMX-101, our lead candidate, is a peripherally-acting, GPCR-mixed opioid agonist/antagonist that is orally bioavailable and achieves significant systemic blood levels without crossing the blood-brain barrier.  

In preclinical studies, DMX-101 demonstrated potent anti-hyperalgesic and anti-inflammatory nociceptive effects. In an exploratory Phase 2 trial of 12-week daily dosing in 320 patients with IBS-D, DMX-101 was shown to be safe with no signs or symptoms of CNS exposure, while showing a strong signal of analgesic efficacy. There were no cases of abuse, withdrawal symptoms, tolerance development, pupillary constriction, or other neurologic effects typically observed with opioids.